Clinical implications of regorafenib-induced hypothyroidism in metastatic colorectal cancer refractory to standard therapies: A prospective evaluation

被引：0
|
作者：
Kim, J. H. [1 ]
Kim, J. E. [1 ]
Kim, S. Y. [1 ]
Kim, K-P. [1 ]
Hong, Y. S. [1 ]
Kim, T. W. [1 ]
机构：
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
598P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The efficacy and safety of apatinib in patients with metastatic colorectal cancer refractory to standard therapies.
    Lv, Wangxia
    Yuan, Meiqin
    Yang, Yunshan
    Shi, Zhong
    Zhong, Haijun
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Imaging and clinical correlates with regorafenib in metastatic colorectal cancer
    Khan, Khurum
    Cascinu, Stefano
    Cunningham, David
    Kim, Sun-Young
    Oki, Eiji
    Seery, Tara
    Shen, Lin
    Siena, Salvatore
    Tournigand, Christophe
    Turhal, Nazim Serdar
    Hendlisz, Alain
    CANCER TREATMENT REVIEWS, 2020, 86
  • [23] Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer
    Kim, Seung Tae
    Kim, Tae Won
    Kim, Kyu-Pyo
    Kim, Tae-You
    Han, Sae-Won
    Lee, Ji Yun
    Lim, Sung Hee
    Lee, Min-Young
    Kim, Haesu
    Park, Young Suk
    CANCER RESEARCH AND TREATMENT, 2015, 47 (04): : 790 - 795
  • [24] FOLFOX rechallenge versus regorafenib in patients with metastatic colorectal cancer refractory to standard chemotherapy: A retrospective analysis.
    Calegari, Maria Alessandra
    Zurlo, Ina Valeria
    Di Stefano, Brunella
    Camarda, Floriana
    Di Dio, Carmela
    Garufi, Giovanna
    Cassano, Alessandra
    Barone, Carlo Antonio
    Bria, Emilio
    Basso, Michele
    Orlandi, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [25] Trifluridine/tipiracil or regorafenib in refractory metastatic colorectal cancer patients: An AGEO prospective "real life" study.
    Coutzac, Clelia
    Trouilloud, Isabelle
    Artru, Pascal
    Henriques, Julie
    Masson, Therese
    De La Fouchardiere, Christelle
    Doat, Solene
    Bouche, Olivier
    Coriat, Romain
    Saint, Angelique
    Moulin, Valerie
    Vernerey, Dewi
    Tougeron, David
    Taieb, Julien
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] New standard of care for refractory metastatic colorectal cancer
    Nierengarten, Mary Beth
    CANCER, 2023, 129 (12) : 1789 - 1790
  • [27] The impact of primary tumor sidedness on the effect of regorafenib in refractory metastatic colorectal cancer
    Yoon, Sang Eun
    Hur, Joon Young
    Lee, Su Jin
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Lim, Ho Yeong
    Kang, Won Ki
    Park, Young Suk
    Kim, Seung Tae
    CANCER RESEARCH, 2019, 79 (13)
  • [28] Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study
    Xu, Donghao
    Liu, Yu
    Tang, Wentao
    Xu, Lingsha
    Liu, Tianyu
    Jiang, Yudong
    Zhou, Shizhao
    Qin, Xiaorui
    Li, Jisheng
    Zhao, Jiemin
    Ye, Lechi
    Chang, Wenju
    Xu, Jianmin
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [29] A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer
    Xue, Wu-Song
    Men, Si-Ye
    Liu, Wei
    Liu, Reng-Hai
    MEDICINE, 2018, 97 (40)
  • [30] Regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer: The optimization of pharmacological costs
    Giuliani, J.
    Bonetti, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 62 - 62
12345